about
Pre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging.Brain metabolic changes in Hodgkin disease patients following diagnosis and during the disease course: An 18F-FDG PET/CT study.Initial staging of Hodgkin's disease: role of contrast-enhanced 18F FDG PET/CTBrentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses.Surgical management of rhinosinusitis in onco-hematological patientsPercutaneus osteoplasty in the treatment of extraspinal painful multiple myeloma lesions.Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor.Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro.Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients.Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma?Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study.Psoriasiform sarcoidosis: an unusual variety.Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma.BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant.Recurrent Sweet's syndrome in a patient with multiple myelomaCLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)Systemic Therapy of Primary Cutaneous B-cell Lymphoma, Marginal Zone Type, with Rituximab, a Chimeric Anti-CD20 Monoclonal AntibodyNew reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophiliaMolecular Expression of Bone Marrow Angiogenic Factors, Cell-Cell Adhesion Molecules and Matrix-Metallo-Proteinases in Plasmacellular Disorders: a Molecular Panel to İnvestigate Disease ProgressionClinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemiaFinal results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS disseminationAssociation between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship?Recombinant interferon alfa-2b (Intron A) as post-induction therapy for responding multiple myeloma patients. M84 protocolPhase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphomaCytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-alpha (IFN-alpha) therapyFISH analysis for CML monitoring?Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin diseasePositive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumorsSezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusionSimultaneous occurrence of BCR/ABL1 and RUNX1/RUNX1T1 in a case of therapy-related acute myeloid leukemiaFactors affecting intrapatient liver and mediastinal blood pool ¹⁸F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphomaGenetic analysis of erythrocytosis reveals possible causative and modifier gene mutationsBlood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevancePreliminary results of a counselling programme for fertility preservation in female cancer patients: The experience of the GEMME DORMIENTI networkImpact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patientsDiagnostic Performance and Safety of Bronchoalveolar Lavage in Thrombocytopenic Haematological Patients for Invasive Fungal Infections Diagnosis: A Monocentric, Retrospective ExperienceRemission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravirThe neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network 'Rete Ematologica del Lazio per i Linfomi' (RELLI)
P50
Q30833769-5E4E9E44-D2F7-4A49-9EEA-325FD4E9ECF1Q34993792-F124515C-2296-4F95-8E4A-9DCA9BFB2179Q36150877-72FF57A7-415F-4C34-94BD-FE8F946099E0Q36371623-2B87CA26-1709-40A5-A1EE-10816C1A6F3EQ37821961-208912D1-6DD7-4010-A7D8-9C2C5CAC7655Q38272990-0649434B-EC48-4FA6-9059-8F398D8D5696Q39285366-117CAABC-32EE-454C-B5F3-CDED89CC2D7DQ39541924-66F8D32F-E344-4511-960B-7FE416D97939Q40607052-10CE5CE2-7430-4034-BE33-9DA215EF6C0CQ42166373-AE4C4814-820E-4ED3-A260-D991A67595DAQ42926639-83E4C3EF-10A6-4966-823E-7F1EF86FC7B5Q48318320-66E76965-05C5-40E1-865C-2102098C8D4BQ48706111-2A1E76C4-AC26-4405-A907-179AA78B5AC5Q49715572-D239D522-7C58-4D2F-86BD-0BF2D70C39AFQ50016992-40EF50F1-6400-40FC-8999-2E5F63F3C00CQ50025568-74A49A09-C945-4A33-A461-D9C44AAE8D8CQ57823682-222FC203-532A-493C-8BC6-15F027BC360FQ57903207-55E1F387-CE75-4719-B13E-5A0068A3CD0AQ58435086-A9FF0EB7-433E-45A3-89BE-86D85A932BDBQ58449125-0534FA46-E458-4E81-BE4D-7A1F163A687EQ58701104-DB576BE8-84B5-4424-B781-EA842EC1B05FQ60358526-38B6649E-E435-4FCE-B680-56803C23EDCEQ61601896-EB594B59-D7B9-4E6F-8D81-6AF2A63AEB5CQ64076146-4D56C5C9-9DFD-4D98-9872-23A2BBCB3055Q68126734-11C1D408-C98F-4294-98E7-3A91F004856DQ70820486-2A1BF51A-8DA7-4545-9218-544F00A0AD79Q71581366-887C5CA4-FCAD-41B7-B970-2B31C219FF8EQ71614353-7E5D817A-DF1C-4752-B65D-27207C60EBA0Q73368641-C8A38AC2-D096-43E2-90A5-F12401A9E20EQ74469972-6080D234-C4B0-4530-807F-5FC956C7B8F1Q82270526-E15796FD-B113-4B78-AA8A-3C6CA4E8E7F4Q84984967-15CB89CA-BC00-48DF-A08C-633A0F661355Q87345549-269AC521-F6AD-407F-A1E5-757CC939BA59Q90261169-C50BD8F1-346C-4D56-9E1F-034817EB3C86Q90288069-36B1CA99-9B4F-4733-BB4E-782756C5D6FFQ90393985-BC9D8AD1-C4FD-49D8-B87D-ED8DA99DC11CQ90414401-D05D6215-4E83-465A-8A10-0E36F1A98E8EQ91176291-23A555EF-D91D-4564-A27B-C827317E0C15Q92221509-C7BD8F78-ECD2-4717-8B87-C3A4E84A101CQ93155607-83627F4F-A6C6-45DA-B795-53EACED13C44
P50
description
researcher ORCID ID = 0000-0003-4586-0920
@en
wetenschapper
@nl
name
Maria Cantonetti
@ast
Maria Cantonetti
@en
Maria Cantonetti
@es
Maria Cantonetti
@nl
type
label
Maria Cantonetti
@ast
Maria Cantonetti
@en
Maria Cantonetti
@es
Maria Cantonetti
@nl
prefLabel
Maria Cantonetti
@ast
Maria Cantonetti
@en
Maria Cantonetti
@es
Maria Cantonetti
@nl
P106
P1153
6603769431
P21
P31
P496
0000-0003-4586-0920